EnteroMedics' Maestro technology is nervous wreck, trial shows
This article was originally published in Clinica
Executive Summary
The Maestro system, a neuromodulation therapy developed by EnteroMedics to treat obesity, has failed to show efficacy in a pivotal trial. The firm is now in the process of selling off more than six million shares to raise cash.